開放式骨折的發生常伴隨著複雜的治療流程，而在開放式骨折的治療初期，常常需施加抗生素以預防感染的風險。此外，抗生素的施加，常常為了達到有效的治療效果，需要定時定量的植入於人體中，而藥物載體的應用能夠有效控制藥物的釋放亦能減少藥物植入人體的次數。在老年人的骨折事件中，老年人的骨骼修復能力較為不佳。而生物活性玻璃(BG)是一個具有優異生物活性的骨植入物以及藥物載體，其在浸入模擬體液後會於表面上形成氫氧基磷灰石層能夠有效幫助骨骼的修復。而在藥物載體的研究中，提高比表面積與孔體積能夠有效影響材料的載藥量，而具有高比表面積介孔生物活性玻璃(MBG)亦為目前的主流材料。此外，溶膠-凝膠法、噴霧熱解法(Spray pyrolysis , SP)是兩種常見的製備MBG方法，雖然SP相較於溶膠-凝膠法具有低成本且快速製造時間的優勢，但是於SP的製程中使用介面活性劑時會因為燒結時間短，而導致有碳殘留的問題，且介面活性劑因缺乏高度有序的微粒結構易產生團聚現象，導致MBG的比表面積減少。為了克服上述問題，在本研究中分別添加0、25、40、50以及69 vol% 雙氧水以合成MBG。而在本實驗結果顯示具有高比表面積以及具有較高孔徑大小的樣品具有較高的藥物釋放情況。

The occurrence of the open fractures is often accompanied by complex treatment procedures. In the early stages of treatment for the open fracture, antibiotics are often required to prevent the risk of infection. In addition, in order to achieve an effective therapeutic effect, antibiotics require regular quantitative implantation for the human body. The application of the drug carrier can effectively control the release of the drug and also reduce the number of times to implant the drug into the human body. In the bone fractures of the elderly, the skeletal reparability of the elderly is relatively poor. Bioactive glass is a potential biomaterial for bone implants and drug carriers because it has excellent bioactivity and forms a hydroxyl apatite (HA) layer when immersed in body fluid. In the research of drug carriers, increasing the specific surface area and pore volume can effectively affect the drug loading of the material. One product of these studies is mesoporous bioactive glass (MBG), which has a high specific surface. The common pore-forming agents of MBG are surfactants; however, surfactants present the serious problems of micelle aggregation and carbon contamination.
To overcome these problems, hydrogen peroxide (H2O2) has been used as a pore-forming agent to replace the traditional surfactants, such as P123, and F127. In this study, 0, 25, 40, 50, and 69 vol% H2O2-treated MBG powders were synthesized using spray pyrolysis (SP). The corresponding formation mechanisms are also discussed. The results shows that samples with high specific surface area and high pore size have higher drug release.

[1] D. G. Steele, The anatomy and biology of the human skeleton, Texas A and M University Press, 1988.
[2] J. J. B. Anderson, Calcium, phosphorus and human bone development, J. Nutr., 126 (1996) 1153S-1158S.
[3] M. H. Yoshimura, A. Nimura, A. Yokoyama, H. Koga, and I. Sekiya, Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle, Cell Tissue Res., 327 (2007) 449-462.
[4] B. Wittich, Keep those volunteers around, Knowledge transfer publishing, 2002.
[5] P. H. Gray, and R. Howden, The classic collector’s edition. Gray’s anatomy, New york: Churehill livingstone inc, (1977) 459-460.
[6] E. P. Solomon, Human anatomy and physiology, Saunders College Publishing, 1983.
[7] G. J. Tortora, Principles of anatomy and physiology (ed 6) harper and row, New York, 1990.
[8] https://brianrmz.weebly.com/bone-composition.html.
[9] http://www.hkpe.net/hkdsepe/fitness_nutrition/osteoporosis.htm.
[10] A.C. Guyton, Guyton human physiology and mechanism of disease, WB Saunders Co. Penn USA, 1991.
[11] K. S. Brooks, Enteral and parenteral nutrition, Present knowledge in nutrition, 7th edition, Ziegler EE, Filere Jr LJ, eds, ILSI Press Washington DC, USA, (1996) 530-539.
[12] E. N. Whitney, Table of food composition, Whitney, EN; Rolfes, SR Understanding nutrition. Belmont: ITP, cap. H (appendix), p. H-1–H-89, (1999).
[13] D. S. R. Rolfes, and E. N. Whitney, Life span nutrition: conception through life, Wadsworth Publishing Company, Inc.1998.
[14] https://studentradiographer.com/?p=3665.
[15] https://www.orthobullets.com/trauma/1003/gustilo-classification.
[16] M. R. B. Gustilo, and D. N. Williams, Problems in the management of type III (severe) open fractures: a new classification of type III open fractures, J. Trauma Acute Care 24 (1984) 742-746.
[17] A. Adler, C. Rosenberg, R. Pivec, B. H. Kapadia, V. Nadarajah, Q. Nziri, S. F. Harwin, and C. B. Paulino, In-hospital mortality following open and closed long bone fracture: A comparative study, Surg. Technol. Int. , 26 (2015) 337-342.
[18] B. K. Okike, Trends in the management of open fractures: a critical analysis, J. Bone. Joint. Surg. Am., 88 (2006) 2739-2748.
[19] D. J. Pavani, K. Nagaraju, T. Regupathi, K. N. V. Rao, and K. R. Dutt, Formulation development and in vitro evaluation of sustained release matrix tablets of tramadol hydrochloride, Innovat international journal of medical and pharmaceutical sciences, 2 (2017).
[20] A. Meyerhoff, US food and drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis, Clin. Infect. Dis., 28 (1999) 42-48.
[21] Z. S. Freiberg, Polymer microspheres for controlled drug release, Int. J. Pharm. , 282 (2004) 1-18.
[22] L. A. Z. Wang, and O. C. Farokhzad, Nanoparticle delivery of cancer drugs, Annu. Rev. Med., 63 (2012) 185-198.
[23] B. E. F. Craparo, G. Pitarresi, and G. Cavallaro, Nanoparticulate systems for drug delivery and targeting to the central nervous system, CNS Neurosci. Ther., 17 (2011) 670-677.
[24] B. S. Vrignaud, and P. Saulnier, Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles, Biomater. , 32 (2011) 8593-8604.
[25] C. M. J. Hu, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer, Biochem. Pharmacol. , 83 (2012) 1104-1111.
[26] R. M. Vallet-Regi, R. P. Del Real, and J. Pérez-Pariente, A new property of MCM-41: drug delivery system, Chem. Mater. , 13 (2001) 308-311.
[27] B. M. Vallet‐Regí, and D. Arcos, Mesoporous materials for drug delivery, Angew. Chem. Int. Ed. , 46 (2007) 7548-7558.
[28] B. M. Vallet-Regí, M. Colilla, and M. Manzano, Drug confinement and delivery in ceramic implants, Drug metabolism letters, 1 (2007) 37-40.
[29] T. P. T. Azaïs, F. Aussenac, N. Baccile, C. Coelho, J. M. Devoisselle, and F. Babonneau, Solid-state NMR study of ibuprofen confined in MCM-41 material, Chem. Mater. , 18 (2006) 6382-6390.
[30] C. L. Ward, and E. W. Davis, Controlled release of tetracycline–HCl from halloysite–polymer composite films, J. Nanosci. Nanotechno., 10 (2010) 6641-6649.
[31] T. Govender, S. Stolnik, M.C. Garnett, L. Illum, S.S. Davis, PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug, J. Controlled Release 57 (1999) 171-185.
[32] S. J. M. Anderson, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug deliv. Rev., 28 (1997) 5-24.
[33] K. Garg, Bone, Quintessence Publishing2004.
[34] T. Q. Xu, and J. T. Czernuszka, Encapsulation and release of a hydrophobic drug from hydroxyapatite coated liposomes, Biomater. , 28 (2007) 2687-2694.
[35] Y. L. Zhao, X. Zhou, L. Zhou, H. Wang, J. Tang, and C. Yu, Mesoporous bioactive glasses for controlled drug release, Microporous Mesoporous Mater. , 109 (2008) 210-215.
[36] M. P. Ginebra, T. Traykova, J.A. Planell, Calcium phosphate cements as bone drug delivery systems: a review, J. Controlled Release 113 (2006) 102-110.
[37] J. A. DiPisa, and A. T. Berman, The temperature problem at the bone-acrylic cement interface of the total hip replacement, Clin. Orthop. Relat. R., (1976) 95-98.
[38] L. Linder, Reaction of bone to the acute chemical trauma of bone cement, J. Bone. Joint. Surg. Am., 59 (1977) 82-87.
[39] P. L. Avérous, Biodegradable polymers, Environmental silicate nano-biocomposites, Springer2012, pp. 13-39.
[40] C. Bastioli, Handbook of biodegradable polymers, iSmithers Rapra Publishing2005.
[41] S. S. E. Bae, K. Park, and D. K. Han, Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine, J. Controlled Release 133 (2009) 37-43.
[42] W. F. Y. Cheng, C. H. Su, T. L. Tsai, P. C. Wu, D. B. Shieh, J. H. Chen, P. C. H. Hsieh, and C. S. Yeh, Stabilizer-free poly (lactide-co-glycolide) nanoparticles for multimodal biomedical probes, Biomater. , 29 (2008) 2104-2112.
[43] D. Groot, Bioceramics of calcium phosphate, J. Clin. Eng., 9 (1984) 52.
[44] D. Groot, Medical applications of calciumphosphate bioceramics, J. Ceram. Soc. Jpn. , 99 (1991) 943-953.
[45] B. M. Stigter, K. De Groot, and P. Layrolle, Incorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy, J. Controlled Release 99 (2004) 127-137.
[46] U. V. Uskoković, Nanosized hydroxyapatite and other calcium phosphates: chemistry of formation and application as drug and gene delivery agents, J. Biomed. Mater. Res. B 96 (2011) 152-191.
[47] K. E. Verron, J. Guicheux, and J. M. Bouler, Calcium phosphate biomaterials as bone drug delivery systems: a review, Drug Discov. Today, 15 (2010) 547-552.
[48] H. K. Ariga, A. Vinu, and M. Hartmann, Biomaterials in mesoporous media: from open space to confined space, American Scientific Publishers2005.
[49] L. L. Hench, W. C. Allen, and T. K. Greenlee, Bonding mechanisms at the interface of ceramic prosthetic materials, J. Biomed. Mater. Res. A 5(1971) 117-141.
[50] L.L. Hench, Bioceramics: from concept to clinic, J. Am. Ceram. Soc. , 74 (1991) 1487-1510.
[51] P. Ducheyne, Bioceramics: material characteristics versus in vivo behavior, J. Biomed. Mater. Res., 21 (1987) 219.
[52] M. Vallet-Regí, Mesoporous silica nanoparticles: their projection in nanomedicine, ISRN Mater. Sci. , 2012 (2012).
[53] J. S. Earl, K. H. Muller, R. M. Langford, and D. C. Greenspan, Physical and chemical characterization of dentin surface following treatment with NovaMin technology, J. Clin. Dent 22 (2011) 62-67.
[54] R. Q. Chang, D. L. Chen, X. Y. Yue, L. Yu, and C. P. Zhang, An in-vitro investigation of iron-containing hydroxyapatite/titanium composites, J. Mater. Sci. Technol. , 27 (2011) 546-552.
[55] T. S. Giri, M. P. Stellmaker, and V. S. Y. Lin, Stimuli‐responsive controlled‐release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles, Angew. Chem. Int. Ed. , 44 (2005) 5038-5044.
[56] A. E. Clark, L. L. Hench, Auger spectroscopic analysis of bioglass corrosion films, J. Am. Ceram. Soc. , 59 (1976) 37-39.
[57] D. M. Sanders, Mechanisms of glass corrosion, J. Am. Ceram. Soc. , 56 (1973) 373-377.
[58] J. Wilson, An introduction to bioceramics, World scientific1993.
[59] B. Lei, Y. Wang, N. Zhao, C. Du, and L. Fang, Synthesis and bioactive properties of macroporous nanoscale SiO2–CaO–P2O5 bioactive glass, J. Non-Cryst. Solids 355 (2009) 2678-2681.
[60] J. Sun, L. Li, W. Zhao, J. Gao, M. Ruan, and J. Shi, Functionalization and bioactivity in vitro of mesoporous bioactive glasses, J. Non-Cryst. Solids 354 (2008) 3799-3805.
[61] C. J. Shih, L. F. Huang, P. S. Lu, H. F. Chang, and I. F. Chang, Synthesis and in vitro bioactivity of mesoporous bioactive glass scaffolds, Mater. Sci. Eng., C 30 (2010) 657-663.
[62] X .Yan, L. Zhao, J. Yi, H. Deng, L. Wang, G. M. Lu, and C. Yu, Synthesis and in vitro bioactivity of ordered mesostructured bioactive glasses with adjustable pore sizes, Microporous Mesoporous Mater. , 132 (2010) 282-289.
[63] G. Wei, J. Yi, L. Zhao, L. Zhou, Y. Wang, and C. Yu, Synthesis and in-vitro bioactivity of mesoporous bioactive glasses with tunable macropores, Microporous Mesoporous Mater. , 143 (2011) 157-165.
[64] C. R. Li, and L. L. Hench, An investigation of bioactive glass powders by sol‐gel processing, J. Appl. Biomater. , 2 (1991) 231-239.
[65] A. J. Jones, Bio-glasses: an introduction, John Wiley & Sons2012.
[66] M. Vallet-Regí, Evolution of bioceramics within the field of biomaterials, C. R. Chim. , 13 (2010) 174-185.
[67] I. Izquierdo-Barba, J. C. Doadrio, J. M.González-Calbet, and M. Vallet-Regí, Tissue regeneration: a new property of mesoporous materials, Solid State Sci., 7 (2005) 983-989.
[68] W.X. Z. Jinzhu, L. Lude, and X. Yingbin, Mutual transfer mechanism of crack and craze of toughening and reforceing of plastics modified by inorganic nanoparticles, Engineering plastics application, 1 (2003) 006.
[69] M. Mačković, R. Detsch, D. Mohn, W. J. Stark, E. Spiecker, A. R. Boccaccini, Bioactive glass (type 45S5) nanoparticles: in vitro reactivity on nanoscale and biocompatibility, J. Nanopart. Res. , 14 (2012) 966.
[70] Y. Li, Y. Fan, J. Ma, Thermal, physical and chemical stability of porous polystyrene-type beads with different degrees of crosslinking, Polym. Degrad. Stab. , 73 (2001) 163-167.
[71] M. Yang, B. Zibrowius, and F. Schüth, Formation of cyanide-functionalized SBA-15 and its transformation to carboxylate-functionalized SBA-15, Phys. Chem. Chem. Phys. , 6 (2004) 2461-2467.
[72] H. J. Chung, J. W. Bae, I. K. Jung, J. W. Lee, and K. D. Park, Synthesis and characterization of Pluronic® grafted chitosan copolymer as a novel injectable biomaterial, Curr. Appl. Phys., 5 (2005) 485-488.
[73] R. F. Walsh, Pressure effects on hydrogen peroxide decomposition temperature, Schafer corp calabasas ca, 2002.
[74] X. Yan, X. Zhou, J. Tang, and D. Zhao, Highly ordered mesoporous bioactive glasses with superior in vitro bone‐forming bioactivities, Angew. Chem. Int. Ed. , 43 (2004) 5980-5984.
[75] P. Mukerjee, Critical micelle concentrations of aqueous surfactant systems, National Standard reference data system, 1971.
[76] G. D. Miles, Minima in surface tension–concentration curves of solutions of sodium alcohol sulfates, J. Phys. Chem. C., 48 (1944) 57-62.
[77] https://www.google.com.tw/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&ved=2ahUKEwiz4ouN_ZPcAhWCVhQKHZ6RBxkQjhx6BAgBEAM&url=https%3A%2F%2Fwww.slideshare.net%2Fdrmadihamushtaque%2Fdetermination-of-cmc&psig=AOvVaw18_Qd9od8yNgo5JADJ4osa&ust=1531293001263396.
[78] R. A. Martin, J. V. Hanna, P. D. Lee, R. J. Newport, M. E. Smith, and J. R. Jones, Characterizing the hierarchical structures of bioactive sol–gel silicate glass and hybrid scaffolds for bone regeneration, Philos. Trans. R. Soc. London, Ser. A, 370 (2012) 1422-1443.
[79] J.J. Ebelmen, Prepn from abs alcohol and silicon tetrachloride, Ann, 57 (1846) 319-355.
[80] W. Geffcken, E. Berger, German patent 736,411, Google scholar, (1939).
[81] H. Dislich, New routes to multicomponent oxide glasses, Angew. Chem. Int. Ed. , 10 (1971) 363-370.
[82] J. L. Zhang, Review and modeling of viscosity of silicate melts: Part I. Viscosity of binary and ternary silicates containing CaO, MgO, and MnO, Metall. Mater. Trans. B 29 (1998) 177-186.
[83] C. F. Clement, Gas-to-particle conversion in the atmosphere: II. Analytical models of nucleation bursts, Atmos. Environ. , 33 (1999) 489-499.
[84] S. J. Shih, R. Jatnika, C. J. Shih, and K. B. Borisenko, Control of Ag nanoparticle distribution influencing bioactive and antibacterial properties of Ag‐doped mesoporous bioactive glass particles prepared by spray pyrolysis, J. Biomed. Mater. Res. B 103 (2015) 899-907.
[85] C. Y. Chen, S. C. Tsai, C. K. Lin, and H. M. Lin, Effect of precursor characteristics on zirconia and ceria particle morphology in spray pyrolysis, Ceram. Int. , 34 (2008) 409-416.
[86] S. J. Shih, C. Y. Chen, C. K. Lin, One-step synthesis and characterization of nanosized bioactive glass, J. Medi. Bio. Eng., 34 (2014) 18-23.
[87] S. J. Shih, L. Valentino Posma Panjaitan, and D. Rahayu Meyla Sari, The correlation of surfactant concentrations on the properties of mesoporous bioactive glass, Mater., 9 (2016) 58.
[88] D. S. Liu, Automated system for chemical analysis of airborne particles based on corona-free electrostatic collection, Anal. Chem. , 68 (1996) 3638-3644.
[89] M. C. Kittel, Introduction to solid state physics, Wiley New York1996.
[90] X. C. Lin, C. Z. Yu, S. Ismadji, and G. Q. M. Lu, Periodic mesoporous silica and organosilica with controlled morphologies as carriers for drug release, Microporous Mesoporous Mater. , 117 (2009) 213-219.
[91] B. O. Fowler, Infrared studies of apatites. I. Vibrational assignments for calcium, strontium, and barium hydroxyapatites utilizing isotopic substitution, Inorg. Chem. , 13 (1974) 194-207.
[92] R. J. Bell, Atomic vibrations in vitreous silica, Discuss. Faraday. Soc. , 50 (1970) 55-61.
[93] J.M. Andrews, Determination of minimum inhibitory concentrations, J. Antimicrob. Chemother. , 48 (2001) 5-16.
[94] L.L. Hench, Biomaterials: from concept to clinic, J. Am. Ceram. Soc. , 74 (1991) 1487-1510.
[95] C. W. Xia, Preparation, in vitro bioactivity and drug release property of well-ordered mesoporous 58S bioactive glass, J. Non-Cryst. Solids 354 (2008) 1338-1341.